摘要
目的:探讨培美曲塞联合顺铂治疗晚期肺腺癌的临床疗效及毒性反应。方法:选取晚期肺腺癌患者96例,随机分为PP组与TP组,PP组采用培美曲塞联合顺铂治疗,TP组采用多西他赛联合顺铂治疗,对比两组患者的疾病进展时间(TTP)、生存期(OS)和毒性反应。结果:PP组Ⅲ~Ⅳ度白细胞减少病例少于TP组(P<0.05),Ⅲ~Ⅳ度血小板减少病例少于TP组(P<0.05),两组疗效和生存率比较差异无统计学意义(P>0.05)。结论:两种方案治疗晚期肺腺癌均具有较好的耐受性和临床疗效,应根据患者临床特点,选择个体化治疗。
Objective： To discuss the clinical efficacy and toxic reaction of combined therapy of pemetrexed disodium and eis-platinum in treating advanced lung adenocarcinoma. Methods： A total of 96 patients with advanced lung adenocarcinoma were enrolled and divided into PP group and TP group ran- domly. Patients in PP group received combined therapy of pemetrexed disodium and eis-platinum while those in TP group adopted combined therapy of docetaxel and cis-platinum. Time to progress, overall re- sponse and toxic reaction in two groups were observed for comparison. Results： Reduction of white blood cell of III-Ig degrees in PP groups was smaller than that in TP group （P^0.05）, while reduction of Ill-IV degree blood platelet was smaller than TP group （P〈0.05）. No statistical differences were observed be- tween two groups in efficacy or survival rate （P〈0.05）. Conclusion： Both therapies are with good surviv- ability and clinical efficacy in treating advanced lung adenoearcinoma. Individualized treatment should be chosen according to clinical characteristics of patients,
出处
《海南医学院学报》
CAS
2013年第11期1549-1551,共3页
Journal of Hainan Medical University
基金
中国高校医学期刊临床专项资金项目(112210854)~~
关键词
培美曲塞二钠
多西他赛
晚期肺腺癌
联合化疗
Pemetrexed disodium
Docetaxel
Advanced lung adenocarcinoma
Combined chemo-therapy
